Herceptin: From the bench to the clinic

Cancer Investigation

Volumn 19, Issue 1, 2001, Pages 49-56

  Colomer, R ^a   Shamon, L A ^a   Tsai, M S ^a   Lupu, R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; GROWTH INHIBITOR; PACLITAXEL; PROTEIN TYROSINE KINASE; TRASTUZUMAB;

ADULT; ANTIGEN BINDING; ASTHENIA; BREAST CANCER; CANCER INVASION; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DAMAGE; FEVER; FOOD AND DRUG ADMINISTRATION; GENE OVEREXPRESSION; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIGNAL TRANSDUCTION; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; HEART; HUMANS; NEOPLASM METASTASIS; RECEPTOR, ERBB-2;

EID: 0035083604     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-100000074     Document Type: Review

References (45)

1. erbB-2 amplification in breast cancer with a high rate of proliferation
2. Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failure
3. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
4. The biology erbB-2/neu/HER-2 and its role in cancer
5. c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients
6. HER-2/neu as a predictive marker of response to breast cancer therapy
7. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumors to tumor necrosis factor
8. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product
9. Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody
10. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
11. p185HER2 signal transduction in breast cancer cells
12. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
13. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
14. Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic
15. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody
16. Prolonged survival of mice with human gastric cancer treated with an anti-c-ErbB-2 monoclonal antibody
17. Characterization of an anti p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth
18. Tyrosine kinase signaling pathways control the expression of retinoic acid receptor-alpha in SK-BR-3 breast cancer cells
19. Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells
20. Overexpression of ERBB-2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene
21. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cell in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
22. Production of functional chimaeric mouse/human antibody
23. A hapten-specific chimaeric IgE antibody with human physiological effector function
24. Engineering antibodies for therapy
25. Replacing the complementarity-determining regions in a human antibody with those from a mouse
26. Reshaping human antibodies for therapy
27. Reshaping human antibodies: Grafting an antilysozyme activity
28. Humanization of an anti-p185HER-2 antibody for human cancer therapy
29. Antigen binding thermodynamics and antiproliferative effects of chimeric and humanized anti-p185HER2 antibody fab fragments
30. X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling
31. Growth inhibition of breast cancer cell lines by combinations of anti-P185HER2 monoclonal antibody and cytokines
32. Control of breast tumor cell growth using a targeted cysteine protease inhibitor
33. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
34. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
35. Phase II study of weekly intravenous recombinant humanized anti-p185HER-2 monoclonal antibody in patients with HER-2/neu overexpressing metastatic breast cancer
36. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
37. Efficacy and safety of herceptin (humanized Anti-HER-2 Antibody) as a single agent in 222 women with HER-2 overexpression who relapsed following chemotherapy for metastatic breast cancer
38. Efficacy and safety of herceptin (Trastuzumab, Humanized Anti-HER-2 Antibody) as a single agent in first-line treatment of HER-2 overexpressing metastatic breast cancer (HER-2+/MBC)
39. p185cerbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: Association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair
40. Addition of herceptin (Humanized Anti-HER-2 Antibody) to first line chemotherapy for HER-2 overexpressing metastatic breast cancer (HER-2+/MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial
41. Overall survival advantage to simultaneous chemotherapy plus the humanized anti-HER2 monoclonal antibody herceptin in HER2-overexpressiong metastatic breast cancer
42. Characterization of cardiac dysfunction in the herceptin (Trastuzumab) clinical trials
43. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225